Involvement of SARS‐CoV‐2 accessory proteins in immunopathogenesis
Microbiology and Immunology · 2024
DOI: 10.1111/1348-0421.13157 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology and Immunology, 2024. Verfasst von Hayato Ito und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19, Virus Replication, Open Reading Frames. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Hokkaido University, Japan Society for the Promotion of Science, Takeda Science Foundation.
Abstract (Originalsprache)
Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is the largest single‐stranded RNA virus known to date. Its genome contains multiple accessory protein genes that act against host immune responses but are not required for progeny virus production. The functions of the accessory proteins in the viral life cycle have been examined, but their involvement in viral pathogenicity remains unclear. Here, we investigated the roles of the accessory proteins in viral immunopathogenicity. To this end, recombinant SARS‐CoV‐2 possessing nonsense mutations in the seven accessory protein open reading frames (ORFs) (ORF3a, ORF3b, ORF6, ORF7a, ORF8, ORF9b, and ORF10) was de novo generated using an early pandemic SARS‐CoV‐2 strain as a backbone. We confirmed that the resultant virus (termed ORF3–10 KO) did not express accessory proteins in infected cells and retained the desired mutations in the viral genome. In cell culture, the ORF3–10 KO virus exhibited similar virus growth kinetics as the parental virus. In hamsters, ORF3–10 KO virus infection resulted in mild weight loss and reduced viral replication in the oral cavity and lung tissue. ORF3–10 KO virus infection led to mild inflammation, indicating that an inability to evade innate immune sensing because of a lack of accessory proteins impairs virus growth in vivo and results in quick elimination from the body. Overall, we showed that SARS‐CoV‐2 accessory proteins are involved in immunopathogenicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
- Institute for Vaccine Research and Development (IVReD), Hokkaido University, Sapporo, Japan.
- One Health Research Center, Hokkaido University, Sapporo, Japan.
- Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
- Institute for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido University, Sapporo, Japan.
- Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan.
Förderung
- Hokkaido University
- Japan Society for the Promotion of Science
- Takeda Science Foundation
- Hokuto Foundation for Bioscience
- Hirose Foundation
- Japan Agency for Medical Research and Development
Zitieren
APA
Ito, H., Tamura, T., Wang, L., Mori, K., Tsuda, M., Suzuki, R., Suzuki, S., Yoshimatsu, K., Tanaka, S., & Fukuhara, T. (2024). Involvement of SARS‐CoV‐2 accessory proteins in immunopathogenesis. Microbiology and Immunology. https://doi.org/10.1111/1348-0421.13157
Vancouver
Ito H, Tamura T, Wang L, Mori K, Tsuda M, Suzuki R, et al. Involvement of SARS‐CoV‐2 accessory proteins in immunopathogenesis. Microbiology and Immunology. 2024. doi:10.1111/1348-0421.13157
BibTeX
@article{Ito2024,
author = {Ito, Hayato and Tamura, Tomokazu and Wang, Lei and Mori, Kento and Tsuda, Masumi and Suzuki, Rigel and Suzuki, Saori and Yoshimatsu, Kumiko and Tanaka, Shinya and Fukuhara, Takasuke},
title = {Involvement of SARS‐CoV‐2 accessory proteins in immunopathogenesis},
journal = {Microbiology and Immunology},
year = {2024},
doi = {10.1111/1348-0421.13157}
}
EUVIMED